SpyGlass Pharma, Inc. Annual Report: A Plain-English Guide

I’ve put together this guide to help you understand how SpyGlass Pharma performed this year. My goal is to cut through the corporate jargon so you can decide if this company fits your investment goals.

1. What does this company do?

SpyGlass Pharma tackles a major problem: glaucoma. Most patients rely on daily eye drops to manage eye pressure. However, over half of patients struggle to use them consistently, which can lead to permanent vision loss.

SpyGlass is developing the "BIM-IOL System." This is a tiny, long-lasting drug delivery device attached to the lens used during routine cataract surgery. Instead of remembering daily drops, the lens releases a proven glaucoma medication for up to three years.

2. How are they performing?

The company is "pre-revenue," meaning they aren't selling products yet. They are currently focused on proving their technology works.

Early results look promising. In initial human trials, patients saw a 37% reduction in eye pressure after three years, and 95% stopped using daily drops entirely. They have now moved into "Phase 3" clinical trials—the final hurdle before seeking FDA approval. These trials involve 600 patients across 40 U.S. sites.

3. Financial health

Because they aren't selling products, they aren't making a profit. For the year ending December 31, 2025, the company reported a $42.5 million loss. Most of this went toward $31.2 million in research and development.

They spend about $3.5 million in cash each month to fund trials. After their IPO raised $120 million, they have $85 million in cash. This covers their operations through mid-2027. They will likely need to raise more money or find a partner before their 2028 FDA submission date.

4. Major wins and strategic advantages

• The Win: They launched Phase 3 trials in July 2025, hitting their target timeline.
• The "Secret Sauce": The BIM-IOL System is designed for any cataract surgeon to use. SpyGlass believes this could triple the number of surgeons who can treat glaucoma during routine procedures.
• Streamlined Approval: Because they use a drug already approved by the FDA, they are using a faster regulatory pathway. This lets them focus on proving the delivery system works rather than re-testing the drug itself.

5. Key risks

The biggest risk is that they rely on one product. If the FDA denies approval, or if trial data shows safety issues, the company’s value would likely collapse. They also face competition from established giants like Alcon and Glaukos. Finally, the company reported "material weaknesses" in their accounting controls. While they are fixing these, these gaps create a risk of potential financial errors.

6. Future outlook

The plan is clear: finish Phase 3 trials by 2027 and seek approval in 2028. Beyond this, they are developing a "Drug Ring" implant for patients who have already had cataract surgery. This would expand their market to millions of existing glaucoma patients.

---

Final Thought for Investors: SpyGlass Pharma is a classic "all-or-nothing" bet. You are essentially investing in the success of their Phase 3 trials. If you are comfortable with the risks of a pre-revenue biotech company—specifically the need for future funding and the reliance on a single product—the potential to disrupt the glaucoma market is significant. Keep a close eye on their 2027 trial results, as that will be the primary driver of the company's value.